Atara Biotherapeutics (ATRA) to Announce Quarterly Earnings on Monday

Atara Biotherapeutics (NASDAQ:ATRA) is anticipated to release its Q2 2026 results before the market opens on Monday, August 10th. Analysts expect the company to announce earnings of ($0.3150) per share and revenue of $0.55 million for the quarter. Individuals may review the information on the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Tuesday, August 11, 2026 at 4:00 PM ET.

Atara Biotherapeutics (NASDAQ:ATRA) last posted its quarterly earnings data on Tuesday, May 12th. The biotechnology company reported ($0.29) EPS for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.04. The business had revenue of $0.52 million for the quarter, compared to analyst estimates of $2.90 million. Atara Biotherapeutics had a negative return on equity of 79.12% and a negative net margin of 40.91%. On average, analysts expect Atara Biotherapeutics to post $-0 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Atara Biotherapeutics Stock Performance

Atara Biotherapeutics stock traded up $0.03 during midday trading on Monday, reaching $8.41. 8,265 shares of the company were exchanged, compared to its average volume of 804,304. The firm’s 50-day simple moving average is $9.71 and its 200-day simple moving average is $7.03. Atara Biotherapeutics has a 1 year low of $3.92 and a 1 year high of $19.15. The company has a market capitalization of $75.77 million, a price-to-earnings ratio of -12.55 and a beta of 0.12.

Insider Activity

In other news, CEO Anhco Nguyen sold 5,241 shares of the company’s stock in a transaction dated Monday, May 18th. The shares were sold at an average price of $9.13, for a total value of $47,850.33. Following the sale, the chief executive officer owned 137,837 shares in the company, valued at approximately $1,258,451.81. This represents a 3.66% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, major shareholder Innovation Ltd Panacea sold 313,446 shares of the company’s stock in a transaction that occurred on Thursday, May 7th. The shares were sold at an average price of $10.10, for a total value of $3,165,804.60. Following the sale, the insider owned 1,011,000 shares in the company, valued at $10,211,100. The trade was a 23.67% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 321,101 shares of company stock valued at $3,235,695 over the last 90 days. Insiders own 41.20% of the company’s stock.

Institutional Investors Weigh In On Atara Biotherapeutics

A number of institutional investors have recently modified their holdings of the business. Raymond James Financial Inc. bought a new position in Atara Biotherapeutics during the 2nd quarter worth $31,000. Dimensional Fund Advisors LP bought a new position in shares of Atara Biotherapeutics during the fourth quarter worth about $181,000. Walleye Capital LLC acquired a new stake in shares of Atara Biotherapeutics in the 4th quarter worth about $220,000. Marshall Wace LLP bought a new stake in Atara Biotherapeutics in the 2nd quarter valued at about $327,000. Finally, Quadrature Capital Ltd lifted its position in Atara Biotherapeutics by 22.8% in the 4th quarter. Quadrature Capital Ltd now owns 20,321 shares of the biotechnology company’s stock valued at $368,000 after purchasing an additional 3,779 shares during the last quarter. Institutional investors own 70.90% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on ATRA shares. Freedom Capital raised shares of Atara Biotherapeutics from a “strong sell” rating to a “hold” rating in a research note on Monday, May 18th. Weiss Ratings lowered shares of Atara Biotherapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday. Canaccord Genuity Group set a $13.00 price objective on shares of Atara Biotherapeutics and gave the company a “buy” rating in a research note on Friday, May 8th. Finally, Wall Street Zen raised Atara Biotherapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, June 27th. One research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $9.50.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc is a biotechnology company focused on the discovery, development and commercialization of novel T-cell immunotherapies to transform the treatment of cancer and autoimmune disease. Headquartered in South San Francisco, California, Atara leverages its proprietary off-the-shelf allogeneic Epstein-Barr virus (EBV)-directed T-cell platform to generate engineered cell therapies designed to target EBV-driven malignancies and immune-mediated disorders.

The company’s lead product candidate, tabelecleucel, is an off-the-shelf, EBV-specific T-cell therapy in clinical development for the treatment of EBV-positive post-transplant lymphoproliferative disease (PTLD) and other EBV-associated cancers.